Achieve Operational Excellence, Regulatory Compliance & Minimize Risk in R&D & Manufacturing Sites
With changes in drug modalities, moving to cell and gene therapies, the rapidly changing regulations, facilities and processes bring a new wave of challenges for Environmental, Health & Safety professionals.
New sites introduce new and complex risks for EHS experts, meaning there has never been a more crucial time to collaborate and discuss how to ensure a proactive safety-minded culture and reliable program implementation. EHS for Biopharma 2024 provided our audience with the chance to discover the latest innovations in EHS management and ensure you achieve operational excellence during rapid change.
We united an audience of EHS VPs, directors, managers, and specialists with technical and regulatory expertise from the likes of Pfizer, GSK, Novartis, Janssen, Merck, AbbVie, Biogen and Eli Lilly as they strive for the highest standards of EHS during rapid change at their R&D and manufacturing sites.
Our 2024 Partners
2024 Highlights
Eric Knight
Global Head of Environment, Health, Safety & Sustainability,
Ultragenyx Pharmaceutical
"In my role as Global Head of EHS & Sustainability at Ultragenyx, I am passionate about keeping people safe and healthy with a positive impact to our environment. I'm looking forward to this biopharma-specific summit to learn from others in this rapidly changing industry as we bring novel products to patients."
"I am honored to present at this summit focused on bringing EHS professionals in the Biopharma industry together. Biopharma is an ambiguous and fast paced industry as a whole, so bringing EHS professionals together to share their experiences is a wonderful way to get ahead of our ever-changing work environment."
Jay Carima
Director, Environmental, Health, Safety & Security
Sarepta Therapeutics